96 related articles for article (PubMed ID: 25778472)
1. Comparison of volumetric and linear serial CT assessments of lung metastases in renal cell carcinoma patients in a clinical phase IIB study.
Dicken V; Bornemann L; Moltz JH; Peitgen HO; Zaim S; Scheuring U
Acad Radiol; 2015 May; 22(5):619-25. PubMed ID: 25778472
[TBL] [Abstract][Full Text] [Related]
2. Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study.
Felsch M; Zaim S; Dicken V; Lehmacher W; Scheuring UJ
Acta Radiol; 2017 Feb; 58(2):249-255. PubMed ID: 27083205
[TBL] [Abstract][Full Text] [Related]
3. Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Wu G; Liu G; Kong W; Qu J; Suo S; Liu X; Xu J; Zhang J
Eur Radiol; 2017 Sep; 27(9):3574-3582. PubMed ID: 28130612
[TBL] [Abstract][Full Text] [Related]
4. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
5. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
6. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
7. Linear and volume measurements of pulmonary nodules at different CT dose levels - intrascan and interscan analysis.
Hein PA; Romano VC; Rogalla P; Klessen C; Lembcke A; Dicken V; Bornemann L; Bauknecht HC
Rofo; 2009 Jan; 181(1):24-31. PubMed ID: 19085687
[TBL] [Abstract][Full Text] [Related]
8. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
9. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Smith AD; Lieber ML; Shah SN
AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
[TBL] [Abstract][Full Text] [Related]
10. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
11. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of clinical outcomes of antiangiogenic-targeted therapy in patients with pulmonary metastatic renal cell carcinoma using non-contrast-enhanced computed tomography.
Wu GY; Suo ST; Kong W; Jin D; Zhang J; Xu JR
Acad Radiol; 2014 Nov; 21(11):1434-40. PubMed ID: 25097010
[TBL] [Abstract][Full Text] [Related]
13. Comparison of manual and automated size measurements of lung metastases on MDCT images: potential influence on therapeutic decisions.
Pauls S; Kürschner C; Dharaiya E; Muche R; Schmidt SA; Krüger S; Brambs HJ; Aschoff AJ
Eur J Radiol; 2008 Apr; 66(1):19-26. PubMed ID: 17606351
[TBL] [Abstract][Full Text] [Related]
14. Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
Hegde U; Patel V; Kaloudis E
Int J Urol; 2013 Jun; 20(6):644-5. PubMed ID: 23186003
[No Abstract] [Full Text] [Related]
15. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
16. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon.
Ng CS; Wang X; Faria SC; Lin E; Charnsangavej C; Tannir NM
AJR Am J Roentgenol; 2010 Jan; 194(1):166-71. PubMed ID: 20028919
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
[TBL] [Abstract][Full Text] [Related]
18. Lung, liver and lymph node metastases in follow-up MSCT: comprehensive volumetric assessment of lesion size changes.
Wulff AM; Bolte H; Fischer S; Freitag-Wolf S; Soza G; Tietjen C; Biederer J; Heller M; Fabel M
Rofo; 2012 Sep; 184(9):820-8. PubMed ID: 22872601
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography.
Tran LN; Brown MS; Goldin JG; Yan X; Pais RC; McNitt-Gray MF; Gjertson D; Rogers SR; Aberle DR
Acad Radiol; 2004 Dec; 11(12):1355-60. PubMed ID: 15596373
[TBL] [Abstract][Full Text] [Related]
20. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
Bracarda S; Porta C; Boni C; Santoro A; Mucciarini C; Pazzola A; Cortesi E; Gasparro D; Labianca R; Di Costanzo F; Falcone A; Cinquini M; Caserta C; Paglino C; De Angelis V
Eur Urol; 2013 Feb; 63(2):254-61. PubMed ID: 22964169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]